Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Reith

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Atherosclerosis|January 2, 2016
Management of residual risk after statin therapyChristina Reith, Jane Armitage
Current Opinion in Lipidology|October 15, 2014
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?Jemma C Hopewell, Christina Reith, Jane Armitage
Lancet (London, England)|June 12, 2023
Accelerating clinical trials: time to turn words into actionMartin J Landray, Richard Haynes, Christina Reith
The New England Journal of Medicine|December 6, 2013
Randomized clinical trials--removing obstaclesChristina Reith, Martin Landray, Robert M Califf
Journal of the American College of Cardiology|April 25, 2020
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus SeminarDavid Preiss, Jonathan A Tobert, G Kees Hovingh, et al.
Lancet (London, England)|June 11, 2026
Challenges in assessing statin-associated adverse events - Authors' replyChristina Reith, Jonathan R Emberson, David Preiss, et al.
Drug Discovery Today|June 29, 2020
A pragmatic tool for drug discoveryDavid R Bobbitt, Laura Merson, Christina Reith, et al.
The New England Journal of Medicine|September 13, 2013
Randomized clinical trials--removing unnecessary obstaclesChristina Reith, Martin Landray, P J Devereaux, et al.
Kidney International|April 22, 2019
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
Eclinicalmedicine|November 12, 2021
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trialsNatalie Staplin, Alistair J Roddick, Jonathan Emberson, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Atherosclerosis|January 2, 2016
Management of residual risk after statin therapyChristina Reith, Jane Armitage
Current Opinion in Lipidology|October 15, 2014
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?Jemma C Hopewell, Christina Reith, Jane Armitage
Lancet (London, England)|June 12, 2023
Accelerating clinical trials: time to turn words into actionMartin J Landray, Richard Haynes, Christina Reith
The New England Journal of Medicine|December 6, 2013
Randomized clinical trials--removing obstaclesChristina Reith, Martin Landray, Robert M Califf
Journal of the American College of Cardiology|April 25, 2020
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus SeminarDavid Preiss, Jonathan A Tobert, G Kees Hovingh, et al.
Lancet (London, England)|June 11, 2026
Challenges in assessing statin-associated adverse events - Authors' replyChristina Reith, Jonathan R Emberson, David Preiss, et al.
Drug Discovery Today|June 29, 2020
A pragmatic tool for drug discoveryDavid R Bobbitt, Laura Merson, Christina Reith, et al.
The New England Journal of Medicine|September 13, 2013
Randomized clinical trials--removing unnecessary obstaclesChristina Reith, Martin Landray, P J Devereaux, et al.
Kidney International|April 22, 2019
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
Eclinicalmedicine|November 12, 2021
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trialsNatalie Staplin, Alistair J Roddick, Jonathan Emberson, et al.
Pageof 4